Evidence map›Paper›PMID 31768834›Full record

ReviewJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2020

Evolving Strategies to Manage Clostridium difficile Colitis.

Jessica A Bowman, Garth H Utter

Abstract readReview
In one paragraph

Review in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Encapsulins.Annual review of biochemistry · 2022
    Review
  4. Article
  5. Antibiotics (Basel, Switzerland) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jessica A BowmanDepartment of Surgery, University of California, Davis, Medical Center, 2335 Stockton Blvd., Sacramento, CA, 95817, USA.
Garth H UtterDepartment of Surgery, University of California, Davis, Medical Center, 2335 Stockton Blvd., Sacramento, CA, 95817, USA. ghutter@ucdavis.edu.ORCID 0000-0001-7747-3429

Funding

UC Davis Clinical and Translational Science CenterUL1TR001860 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KENYON, NICHOLAS J., LYLES, COURTNEY REES · 2016 to 2025
$47.3M
Quality Safety Comparative Effectiveness Research Training (QSCERT)T32HS022236 · AHRQ · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MELNIKOW, JOY · 2013 to 2018
$2.1M
AHRQ HHS T32 HS022236NCATS NIH HHS UL1 TR001860
6 · The paper itself

Abstract

Clostridium difficile infection remains a common nosocomial illness with a significant impact on health care delivery. As molecular phenotyping of this organism has changed our understanding of its transmission and virulence, so too have diagnostic methods and treatment strategies evolved in recent years. The burden of this infection falls predominantly on elderly patients with comorbidities who have recently received antibiotics. Oral or enteral vancomycin is now preferred for first-line antimicrobial treatment across the disease spectrum, including mild-moderate initial cases. Fidaxomicin (a novel macrolide antibiotic), bezlotoxumab (a monoclonal antibody against toxin TcdB), and fecal microbiota transplantation expand the therapeutic armamentarium, particularly for recurrent infection. Operative treatment should be reserved for patients with fulminant infection, and early identification of patients who would benefit from an operation remains a challenge. Less invasive surgical options-such as laparoscopic diverting ileostomy with colonic irrigation-may improve survival and other outcomes relative to total abdominal colectomy and represent an attractive alternative particularly for frail patients.

Indexed as

Fecal Microbiota TransplantationAnti-Bacterial AgentsAntibodies, MonoclonalBacterial ToxinsBroadly Neutralizing AntibodiesClostridioides difficileColectomyEnterocolitis, PseudomembranousFidaxomicinHumansIleostomyRisk FactorsTherapeutic IrrigationVancomycinAnti-Bacterial AgentsAntibodies, MonoclonalBacterial ToxinsbezlotoxumabBroadly Neutralizing AntibodiesFidaxomicinVancomycinClostridium difficile colitisPseudomembranous colitis

Identifiers

PMID31768834
PMCPMC7031036

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.